

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

POSITIVE PROFIT ALERT

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of the directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) wish to inform the shareholders and potential investors of the Company that, based on the unaudited consolidated management accounts of the Company for the six months ended 30 June 2021 prepared in accordance with Hong Kong Financial Reporting Standards, the Group is expected to record a net profit of approximately RMB600,000,000 for the six months ended 30 June 2021, while the net profit for the six months ended 30 June 2020 is approximately RMB202,800,000.

The increase in profit during the reporting period is mainly contributed from (i) gross profit during the period increase of approximately RMB290,000,000 as continue increase in market prices of intermediate products; (ii) there is no loss on fair value change of embedded derivative components of convertible bonds during current period; and (iii) decrease in finance costs of approximately RMB95,000,000 due to decrease in borrowings and all interest bearing convertible bonds have been converted into shares in 2020.

Excluding the effect of the fair value loss of approximately RMB223,700,000 arising from convertible bonds in last corresponding period, the operating profit from core business for the six months ended 30 June 2021 is increased by approximately 40% as compared to the corresponding period in 2020.

The information in this announcement is only based on the information currently available to the management of the Company. The results of the Group for the six months ended 30 June 2021 have not yet been finalised nor reviewed by the Company’s audit committee and auditor. The final results of the Group for the six months ended 30 June 2021 may be different to the information referred in this announcement.

Detailed unaudited interim results of the Group for the six months ended 30 June 2021 will be published in the forthcoming 2021 interim results announcement and 2021 interim report of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 16 August 2021

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.